Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Status:
RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab. To analyze the efficacy and safety of nimotuzumab combined with sindilizumab and chemotherapy in first-line treatment of advanced or recurrent or metastatic esophageal cancer.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University